There was no apparent difference in efficacy between AZD6244 and temozolomide for the primary endpoint, progression free survival. Although some anti-tumor activity was detected, AstraZeneca, which licensed AZD6244 from Array in 2003, said that it has no plans to progress the drug into Phase III trials.
AstraZeneca added that it is exploring other options to further develop this compound.